FDA 已授予吉利德科学公司的 Trodelvy (sacituzumab govitecan-hziy) 突破性疗法认定 (BTD)，用于治疗在铂类化疗后病情进展的广泛期小细胞肺癌 (ES-SCLC) 成年患者。BTD 基于全球 II 期 ...

Trodelvy received Breakthrough Therapy designation for ES-SCLC after platinum-based chemotherapy, aiming to expedite its development and review. The phase 2 TROPiCS-03 study showed a 41.9% overall ...